White House coronavirus vaccine adviser Moncef Slaoui to divest $12.4 million of Moderna holdings
Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, speaks as President Donald Trump listens during a coronavirus disease response event in the Rose Garden at the White House in Washington, May 15, 2020.
Kevin Lamarque | Reuters
WASHINGTON — Moncef Slaoui, a former Moderna executive who was recently appointed to co-chair the White House coronavirus vaccine project, will divest approximately $12.4 million worth of stock options he has in the pharmaceutical manufacturer, according to representatives from the company and the Department of Health and Human Services.
Slaoui resigned from the board of Moderna last week, when President Donald Trump appointed him to lead Operation Warp Speed, a massive public-private effort often likened to the Manhattan Project, to develop a vaccine for the deadly coronavirus …continued .
[Source: CNBC News]